NATICK, Mass. – Allurion Technologies, Inc. (NYSE: ALUR) has unveiled new data reinforcing the long-term effectiveness of its AI-powered, non-invasive weight loss solution. The findings, presented at the 2025 Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS), include results from two large-scale real-world studies involving nearly 20,000 patients and a separate four-year follow-up cohort, showing the Allurion Program supports sustainable fat loss while preserving muscle mass.
The first study evaluated 19,946 patients using the Allurion Program and found an average total body weight reduction of 12.4% at four months. In addition to weight loss, patients experienced a 6.5% average increase in muscle mass and a 6% rise in lean body mass as a percentage of total body weight. Fat mass decreased by 11.3%, and visceral fat index was reduced by 12.3%. These results suggest the program delivers not only weight loss but also improvements in metabolic health by preserving muscle and reducing fat.
In a second long-term study of 223 patients, the company reported that 89% of weight lost at four months was maintained at the four-year mark. Participants showed an 11.4% average body weight reduction at four months, which remained at 10.1% after four years, with statistically significant results at every checkpoint.
The Allurion Program combines a procedure-less gastric balloon with an AI-powered digital support system, including remote monitoring, telehealth access, secure messaging, and Bluetooth-enabled scales. The integrated platform supports behavior change and long-term maintenance beyond the duration of the gastric balloon, which naturally passes through the body after several months.
“These early and long-term results confirm that the Allurion Program delivers metabolically healthy weight loss and supports patients well beyond the balloon phase,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “The conversation around obesity must move beyond just weight loss. Our approach provides sustainable outcomes by focusing on fat reduction and muscle preservation.”
Mr. John Loy, Head of the Bariatrics Unit at Ireland’s Auralia Clinic, also emphasized the clinical benefits. “With rising obesity rates, we need scalable, non-invasive solutions. The Allurion Program delivers results similar to surgery without the need for anaesthesia or endoscopy,” he said. “Our patients achieved not only significant fat loss but also retained muscle mass, improving their long-term health and vitality.”
Backed by more than 26 peer-reviewed studies, Allurion’s program represents a shift in obesity care, offering a holistic, tech-enabled alternative to traditional bariatric procedures. As it finalizes its FDA submission, the company continues to strengthen its evidence base, aiming to position the Allurion Program as a new standard for non-surgical metabolic weight management.
